bullish
2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties
Xinyao has highlighted this Insight as a Top Pick
324 Views25 Nov 2021 10:39
The article analyzed the 2021 review and 2022 high conviction ideas, including the industry characteristics, the business, the core competitiveness, the forecast and the concerns of related companies.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 13-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron05 Dec 2021
- Ovctek China Inc (300595.CH) - Better See Some Potential Risks Before Making Decisions30 Nov 2021
- China Healthcare Weekly (Nov.26)-Insulin VBP Results, Key Policy On Consumables & Digital Healthcare29 Nov 2021
- 2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties25 Nov 2021
- Eyebright Medical Technology (688050.CH) -The Impact Of Centralized Procurement and Business Outlook23 Nov 2021
- Hygeia Healthcare (6078.HK) 2021H1 - Efficient Expansion and Management Support the Positive Outlook08 Sep 2021
- Hygeia Healthcare Group (6078 HK) - Good Business Model with Large Market Potential19 Jan 2021
x